Je was op zoek naar: deksametazon (Lithouws - Engels)

-deksametazon (steroid) .
-dexamethasone (steroid) .

revlimid ir deksametazon visada vartokite tiksliai taip, kaip nurod gydytojas.
always take revlimid and dexamethasone exactly as your doctor has told you.

-vairius steroidus (pvz., deksametazon, flutikazono propionat, prednizolon);
-various steroids (eg dexamethasone, fluticasone propionate, prednisolone);

nepageidaujamos reakcijos (nr) , stebtos pacientams, vartojusiems lenalidomid/deksametazon.
adverse drug reactions (adrs) observed in patients treated with lenalidomide/dexamethasone:

skiriant deksametazon kartu su ritonaviru, rekomenduojama nuolat atidziai stebti terapin efekt ir nepageidaujamus reiskinius.
careful monitoring of therapeutic and adverse effects is recommended when dexamethasone is concomitantly administered with ritonavir.

pacientai turi pradti vartoti deksametazon 4 mg du kartus per dien per os ar ven 5 dienas pradedant nuo depocyte injekcijos dienos.
patients should be started on dexamethasone 4 mg twice daily orally or intravenously for 5 days beginning on the day of injection of depocyte.

kaip bebt, nra zinoma, ar vaist sveika pasireikst klinikinio vartojimo metu (kartu vartojant deksametazon) .
however, it is not known whether there is an interaction during clinical use (concomitant treatment with dexamethasone) .

dl padidjusios ven trombembolijos rizikos daugybine mieloma sergancioms ir lenalidomid bei deksametazon vartojancioms pacientms nerekomenduojama vartoti sudtins geriamosios kontracepcijos tableci (taip pat zr.
because of the increased risk of venous thromboembolism in patients with multiple myeloma taking lenalidomide and dexamethasone, combined oral contraceptive pills are not recommended (see also section 4.5) .

tuo paciu metu pacientas turi vartoti steroidus (deksametazon) , kad bt lengviau kontroliuojami salutiniai reiskiniai, galintys pasireiksti vartojant s preparat.
the patient should also receive a steroid medicine (dexamethasone) at the same time to help control some of the side effects of the medicine.

atliekant tyrimus, kuri metu velcade buvo lyginamas su deksametazonu, laikotarpis iki ligos progresavimo pradzios buvo vidutiniskai 189 dienos, vartojant velcade, ir 106 dienos, vartojant deksametazon.
in the study comparing velcade with dexamethasone, the time taken for disease progression was on average 189 days with velcade and 106 days with dexamethasone.

tiek paskutiniam anksciau taikytam gydymui atsparia liga sirgusi ligoni, tiek ir pacient, kuri liga nebuvo atspari gydymui, tarpe velcade gydytiems ligoniams nustatyti bendro isgyvenamumo ir atsako gydym rezultatai buvo zenkliai geresni lyginant su deksametazon gavusi pacient grupmis.
both in patients who were refractory to their last prior therapy and those who were not refractory, overall survival was significantly longer and response rate was significantly higher on the velcade arm.

remiantis farmakokinetikos tyrimo populiacijoje duomenimis atliekant ii fazs tyrimus, kartu vartojant deksametazon, prochlorperazin, fenitoin, karbamazepin, ondansetron, h2 receptori antagonistus ar fenobarbital, temozolomido klirensas nesikeicia.
based on an analysis of population pharmacokinetics observed in phase ii trials, co-administration of dexamethasone, prochlorperazine, phenytoin, carbamazepine, ondansetron, h2 receptor antagonists, or phenobarbital did not alter the clearance of temozolomide.

12 deriniu pries gydym tik deksametazonu anksciau gydytiems pacientams su daugybine mieloma.is 353 pacient mm-009 ir mm010 tyrimuose, kurie gavo lenalidomid/deksametazon, 45, 6% buvo 65 met amziaus ir vyresni.
out of 353 patients in the mm-009 and mm-010 studies who received lenalidomide/dexamethasone, 45.6% were aged 65 or over.